ARS Pharmaceuticals Past Earnings Performance
Past criteria checks 0/6
ARS Pharmaceuticals's earnings have been declining at an average annual rate of -13.2%, while the Biotechs industry saw earnings growing at 17.5% annually. Revenues have been growing at an average rate of 141.3% per year.
Key information
-13.25%
Earnings growth rate
13.42%
EPS growth rate
| Biotechs Industry Growth | 17.04% |
| Revenue growth rate | 141.26% |
| Return on equity | -6.83% |
| Net Margin | -16.11% |
| Last Earnings Update | 31 Mar 2025 |
Recent past performance updates
Recent updates
Analysts Have Just Cut Their ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Revenue Estimates By 15%
May 15
80% Coverage And Pediatric Launch Will Expand Global Markets
Rapid payer coverage expansion and pediatric market entry may enhance revenue and ease prescribing burdens with reduced authorization requirements.ARS Pharmaceuticals Has A Blockbuster Candidate
Apr 30Revenues Not Telling The Story For ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) After Shares Rise 28%
Apr 03Downgrade: Here's How Analysts See ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Performing In The Near Term
Mar 26ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions
Feb 06ARS Pharmaceuticals: Demand Curve Is Key Unknown
Nov 20We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow
Sep 13ARS Pharmaceuticals: A Decent Bet For Upside After Neffy Approval
Sep 06ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles
Jun 25We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate
Mar 18ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans
Nov 14Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation
May 12Revenue & Expenses Breakdown
How ARS Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 25 | 97 | -16 | 105 | 0 |
| 31 Dec 24 | 89 | 8 | 72 | 0 |
| 30 Sep 24 | 3 | -49 | 43 | 0 |
| 30 Jun 24 | 1 | -45 | 39 | 0 |
| 31 Mar 24 | 0 | -50 | 43 | 0 |
| 31 Dec 23 | 0 | -54 | 47 | 0 |
| 30 Sep 23 | 0 | -62 | 51 | 0 |
| 30 Jun 23 | 0 | -53 | 39 | 0 |
| 31 Mar 23 | 1 | -42 | 29 | 0 |
| 31 Dec 22 | 1 | -35 | 19 | 0 |
| 30 Sep 22 | 2 | -25 | 10 | 0 |
| 30 Jun 22 | 2 | -25 | 8 | 0 |
| 31 Mar 22 | 4 | -23 | 6 | 0 |
| 31 Dec 21 | 6 | -20 | 5 | 0 |
| 31 Dec 20 | 18 | -1 | 4 | 0 |
Quality Earnings: SPRY is currently unprofitable.
Growing Profit Margin: SPRY is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SPRY is unprofitable, and losses have increased over the past 5 years at a rate of 13.2% per year.
Accelerating Growth: Unable to compare SPRY's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SPRY is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (21.7%).
Return on Equity
High ROE: SPRY has a negative Return on Equity (-6.83%), as it is currently unprofitable.
Return on Assets
Return on Capital Employed
Discover strong past performing companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/19 03:46 |
| End of Day Share Price | 2025/05/16 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ARS Pharmaceuticals, Inc. is covered by 9 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Roanna Clarissa Ruiz | Leerink Partners LLC |
| Andreas Argyrides | Oppenheimer & Co. Inc. |